VOL. XCIV, NO. 247
★ WIDE MOAT STOCKS COMPARISON ★
NO ADVICE
Stock Comparison
DexCom, Inc. vs Novartis AG
Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.
DexCom, Inc.
DXCM · Nasdaq Global Select Market
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into DexCom, Inc.'s moat claims, evidence, and risks.
View DXCM analysisNovartis AG
NOVN · SIX Swiss Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Novartis AG's moat claims, evidence, and risks.
View NOVN analysisComparison highlights
- Moat score gap: DexCom, Inc. leads (82 / 100 vs 65 / 100 for Novartis AG).
- Segment focus: DexCom, Inc. has 1 segment (100% in Continuous glucose monitoring systems); Novartis AG has 5 segments (29.3% in Oncology).
- Primary market structure: Oligopoly vs Oligopoly. Pricing power: Moderate vs Strong.
- Moat breadth: DexCom, Inc. has 5 moat types across 3 domains; Novartis AG has 4 across 3.
Primary market context
DexCom, Inc.
Continuous glucose monitoring systems
Global continuous glucose monitoring systems and glucose biosensing devices
Global, with FY2025 revenue 71.5% United States and 28.5% international
People with diabetes, metabolic-health users, caregivers, clinicians, payors, distributors and pharmacy channels
CGM device manufacturer, disposable sensor supplier, software/data platform and distribution partner
100%
Novartis AG
Oncology
Oncology and hematology branded medicines (including targeted therapies and radioligand therapy)
Global
Oncologists and hospitals; reimbursed by payers; hospital and specialty pharmacy channels
Originator developer, manufacturer, and marketer of oncology therapies
29.3%
Side-by-side metrics
Moat coverage
Shared moat types
DexCom, Inc. strengths
Novartis AG strengths
Segment mix
DexCom, Inc. segments
Full profile >Continuous glucose monitoring systems
Oligopoly
Novartis AG segments
Full profile >Cardiovascular, Renal and Metabolic
Oligopoly
Immunology
Oligopoly
Neuroscience
Oligopoly
Oncology
Oligopoly
Established Brands
Competitive
Want the full wide moat stocks list?
Browse the full ranking of wide moat stocks, updated with moat scores and segment context.
View the moat stocks listLooking for expansion-stage stocks?
Proven models entering the expansion stage with unit economics that work.
View expansion-stage stocksCuration & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.